Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Hepatocellular 1

Interventions

Filgrastim 5Ifosfamide 3Docetaxel 3Carboplatin 3belinostat 2Sunitinib 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Gemcitabine 2Etoposide 2Epirubicin 2Doxorubicin 2toripalimab 1temsirolimus 1tanespimycin 1resiquimod 1poly ICLC 1perifosine 1pegfilgrastim 1pazopanib 1liposomal doxorubicin 1ivosidenib 1etoposide phosphate 1enasidenib 1apatinib 1angiotensin I (1-7) 1alanosine 1Vincristine 1Topotecan 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Chondrosarcoma × Medicare Part B × Clear all
NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Completed
184 enrolled 20 charts
GastrointestinalHead & NeckSarcoma

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡